Evidence map›Paper›PMID 31043533›Full record

ArticleJournal of virology2019

Genome-Wide Approach to the CD4 T-Cell Response to Human Herpesvirus 6B.

Derek J Hanson, Olga Tsvetkova, Guilhem F Rerolle, Alexander L Greninger, Allesandro Sette, Lichen Jing, Victoria L Campbell, David M Koelle

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Derek J HansonDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Olga TsvetkovaDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Guilhem F RerolleDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Alexander L GreningerDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Allesandro SetteDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California, USA.
Lichen JingDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Victoria L CampbellDepartment of Medicine, University of Washington, Seattle, Washington, USA.
David M KoelleDepartment of Medicine, University of Washington, Seattle, Washington, USA dkoelle@medicine.washington.edu.
University of Washington · USBenaroya Research InstituteLa Jolla Institute for Immunology · US

Funding

Understanding and preventing HLA-associated drug reactionsP50GM115305 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PHILLIPS, ELIZABETH, RODEN, DAN M · 2015 to 2019
$13.0M
Training Program in Infectious Diseases in the Immunocompromised HostT32AI118690 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BOECKH, MICHAEL J · 2016 to 2025
$4.0M
NIAID NIH HHS T32 AI118690NIGMS NIH HHS P50 GM115305
6 · The paper itself

Abstract

Human herpesvirus 6 (HHV-6) and cytomegalovirus (CMV) are population-prevalent betaherpesviruses with intermittent lytic replication that can be pathogenic in immunocompromised hosts. Elucidation of the adaptive immune response is valuable for understanding pathogenesis and designing novel treatments. Knowledge of T-cell antigens has reached the genome-wide level for CMV and other human herpesviruses, but study of HHV-6 is at an earlier stage. Using rare-cell enrichment combined with an HLA-agnostic, proteome-wide approach, we queried HHV-6B-specific CD4 T cells from 18 healthy donors with each known HHV-6B protein. We detected a low abundance of HHV-6-specific CD4 T cells in blood; however, the within-person CD4 T-cell response is quite broad: the median number of open reading frame (ORF) products recognized was nine per person. Overall, the data expand the number of documented HHV-6B CD4 T-cell antigens from approximately 11 to 60. Epitopes in the proteins encoded by U14, U90, and U95 were mapped with synthetic peptides, and HLA restriction was defined for some responses. Intriguingly, CD4 T-cell antigens newly described in this report are among the most population prevalent, including U73, U72, U95, and U30. Our results indicate that selection of HHV-6B ORFs for immunotherapy should consider this expanded panel of HHV-6B antigens.

Indexed as

Antigens, ViralCD4-Positive T-LymphocytesCell LineEpitope MappingEpitopes, T-LymphocyteGenome-Wide Association StudyHerpesvirus 6, HumanHumansOpen Reading FramesRoseolovirus InfectionsAntigens, ViralEpitopes, T-LymphocyteantigenCD4 T cellepitopehuman herpesvirus 6

Identifiers

PMID31043533
PMCPMC6600184
OpenAlexW2978602862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.